Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data

Subarna Sinha, Daniel Thomas, Steven Chan, Yang Gao, Diede Brunen, Damoun Torabi, Andreas Reinisch, David Hernandez, Andy Chan, Erinn B. Rankin, Rene Bernards, Ravindra Majeti, David L. Dill

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Two genes are synthetically lethal (SL) when defects in both are lethal to a cell but a single defect is non-lethal. SL partners of cancer mutations are of great interest as pharmacological targets; however, identifying them by cell line-based methods is challenging. Here we develop MiSL (Mining Synthetic Lethals), an algorithm that mines pan-cancer human primary tumour data to identify mutation-specific SL partners for specific cancers. We apply MiSL to 12 different cancers and predict 145,891 SL partners for 3,120 mutations, including known mutation-specific SL partners. Comparisons with functional screens show that MiSL predictions are enriched for SLs in multiple cancers. We extensively validate a SL interaction identified by MiSL between the IDH1 mutation and ACACA in leukaemia using gene targeting and patient-derived xenografts. Furthermore, we apply MiSL to pinpoint genetic biomarkers for drug sensitivity. These results demonstrate that MiSL can accelerate precision oncology by identifying mutation-specific targets and biomarkers.

LanguageEnglish
Article number15580
JournalNature communications
Volume8
DOIs
Publication statusPublished - 31 May 2017
Externally publishedYes

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Sinha, Subarna ; Thomas, Daniel ; Chan, Steven ; Gao, Yang ; Brunen, Diede ; Torabi, Damoun ; Reinisch, Andreas ; Hernandez, David ; Chan, Andy ; Rankin, Erinn B. ; Bernards, Rene ; Majeti, Ravindra ; Dill, David L. / Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. In: Nature communications. 2017 ; Vol. 8.
@article{0de756049e034d59b064e2dca20ae33c,
title = "Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data",
abstract = "Two genes are synthetically lethal (SL) when defects in both are lethal to a cell but a single defect is non-lethal. SL partners of cancer mutations are of great interest as pharmacological targets; however, identifying them by cell line-based methods is challenging. Here we develop MiSL (Mining Synthetic Lethals), an algorithm that mines pan-cancer human primary tumour data to identify mutation-specific SL partners for specific cancers. We apply MiSL to 12 different cancers and predict 145,891 SL partners for 3,120 mutations, including known mutation-specific SL partners. Comparisons with functional screens show that MiSL predictions are enriched for SLs in multiple cancers. We extensively validate a SL interaction identified by MiSL between the IDH1 mutation and ACACA in leukaemia using gene targeting and patient-derived xenografts. Furthermore, we apply MiSL to pinpoint genetic biomarkers for drug sensitivity. These results demonstrate that MiSL can accelerate precision oncology by identifying mutation-specific targets and biomarkers.",
author = "Subarna Sinha and Daniel Thomas and Steven Chan and Yang Gao and Diede Brunen and Damoun Torabi and Andreas Reinisch and David Hernandez and Andy Chan and Rankin, {Erinn B.} and Rene Bernards and Ravindra Majeti and Dill, {David L.}",
year = "2017",
month = "5",
day = "31",
doi = "10.1038/ncomms15580",
language = "English",
volume = "8",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

Sinha, S, Thomas, D, Chan, S, Gao, Y, Brunen, D, Torabi, D, Reinisch, A, Hernandez, D, Chan, A, Rankin, EB, Bernards, R, Majeti, R & Dill, DL 2017, 'Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data', Nature communications, vol. 8, 15580. https://doi.org/10.1038/ncomms15580

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. / Sinha, Subarna; Thomas, Daniel; Chan, Steven; Gao, Yang; Brunen, Diede; Torabi, Damoun; Reinisch, Andreas; Hernandez, David; Chan, Andy; Rankin, Erinn B.; Bernards, Rene; Majeti, Ravindra; Dill, David L.

In: Nature communications, Vol. 8, 15580, 31.05.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data

AU - Sinha, Subarna

AU - Thomas, Daniel

AU - Chan, Steven

AU - Gao, Yang

AU - Brunen, Diede

AU - Torabi, Damoun

AU - Reinisch, Andreas

AU - Hernandez, David

AU - Chan, Andy

AU - Rankin, Erinn B.

AU - Bernards, Rene

AU - Majeti, Ravindra

AU - Dill, David L.

PY - 2017/5/31

Y1 - 2017/5/31

N2 - Two genes are synthetically lethal (SL) when defects in both are lethal to a cell but a single defect is non-lethal. SL partners of cancer mutations are of great interest as pharmacological targets; however, identifying them by cell line-based methods is challenging. Here we develop MiSL (Mining Synthetic Lethals), an algorithm that mines pan-cancer human primary tumour data to identify mutation-specific SL partners for specific cancers. We apply MiSL to 12 different cancers and predict 145,891 SL partners for 3,120 mutations, including known mutation-specific SL partners. Comparisons with functional screens show that MiSL predictions are enriched for SLs in multiple cancers. We extensively validate a SL interaction identified by MiSL between the IDH1 mutation and ACACA in leukaemia using gene targeting and patient-derived xenografts. Furthermore, we apply MiSL to pinpoint genetic biomarkers for drug sensitivity. These results demonstrate that MiSL can accelerate precision oncology by identifying mutation-specific targets and biomarkers.

AB - Two genes are synthetically lethal (SL) when defects in both are lethal to a cell but a single defect is non-lethal. SL partners of cancer mutations are of great interest as pharmacological targets; however, identifying them by cell line-based methods is challenging. Here we develop MiSL (Mining Synthetic Lethals), an algorithm that mines pan-cancer human primary tumour data to identify mutation-specific SL partners for specific cancers. We apply MiSL to 12 different cancers and predict 145,891 SL partners for 3,120 mutations, including known mutation-specific SL partners. Comparisons with functional screens show that MiSL predictions are enriched for SLs in multiple cancers. We extensively validate a SL interaction identified by MiSL between the IDH1 mutation and ACACA in leukaemia using gene targeting and patient-derived xenografts. Furthermore, we apply MiSL to pinpoint genetic biomarkers for drug sensitivity. These results demonstrate that MiSL can accelerate precision oncology by identifying mutation-specific targets and biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85020027175&partnerID=8YFLogxK

U2 - 10.1038/ncomms15580

DO - 10.1038/ncomms15580

M3 - Article

VL - 8

JO - Nature Communications

T2 - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 15580

ER -